Prognostic utility of a glycoprotein tumor-associated antigen (TA90) specific immune complex assay in patients with cancer

Clinical and Applied Immunology Reviews

Volumn 4, Issue 6, 2004, Pages 395-410

  Gupta, Rishab K ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Colon cancer; Immune complex assay; Lung cancer; Melanoma; Prognosis; TA90; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; CANVAXIN; CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ACCURACY; ADOLESCENT; ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CIRCULATION; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; HIGH RISK PATIENT; HOST; HUMAN; IMMUNOCHEMISTRY; IMMUNOGENICITY; LUNG CANCER; LUNG RESECTION; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS POTENTIAL; PATIENT SELECTION; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN SURGERY;

EID: 13944284616     PISSN: 15291049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cair.2004.06.001     Document Type: Review

References (60)

1. A. Jemal R.C. Tiwari T. Murray A. Ghafoor A. Samuels E. Ward et al. Cancer statistics CA Cancer J Clin 54 2004 8-29
2. D.W. Chan M.K. Schwartz Tumor markers: Introduction and general principles. In: E.P. Diamandis H.A. Fritsche H. Lilja D.W. Chan M.K. Schwartz (Eds.) Tumor markers: Physiology, pathobiology, technology, and clinical applications 2002 AACC Press Washington DC 9-17
3. D.W. Chan S. Sell Tumor markers. In: C.A. Burtis E.R. Ashwood (Eds.) Tietz textbook of clinical chemistry 3rd ed. 2001 W.B. Saunders Co. Philadelphia 390-413
4. R.C. Bast Jr. M. Feeney H. Lazarus L.M. Nadler R.B. Colvin R.C. Knapp Reactivity of a monoclonal antibody with human ovarian carcinoma J Clin Invest 68 1981 1331-1337
5. K. Nustad R.C. Bast Jr. T.J. Brien O. Nilsson P. Seguin M.R. Suresh et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: First report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine Tumour Biol 17 1996 196-219
6. R.C. Bast Jr. F.J. Xu Y.H. Yu S. Barnhill Z. Zhang G.B. Mills CA 125: the past and the future Int J Biol Markers 13 1998 179-187
7. R.C. Bast Jr. Status of tumor markers in ovarian cancer screening J Clin Oncol 21 2003 200-205
8. R.C. Bast Jr. N. Urban V. Shridhar D. Smith Z. Zhang S. Skates et al. Early detection of ovarian cancer: Promise and reality Cancer Treat Res 107 2002 61-97
9. S. Skates R. Troiano R.C. Knapp Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum Int J Gynecol Cancer 13 2003 693-696
10. D. Gagne M. Rivard M. Page M. Lepine C. Platon K. Shazand et al. Development of a nonsurgical diagnostic tool for endometriosis based on the detection of endometrial leukocyte subsets and serum CA-125 levels Fertil Steril 80 2003 876-885
11. T. Kasamatsu T. Onda N. Katsumata M. Sawada T. Yamada R. Tsunematsu et al. Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus Br J Cancer 88 2003 245-250
12. M. Santala A. Talvensaari-Mattila A. Kauppila Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer Anticancer Res 23 2003 3097-3103
13. E. Andersson P. Henderikx E. Krambovitis H.R. Hoogenboom C.A.K. Borrebaeck A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells Cancer Immunol Immunother 47 1999 249-256
14. V. Karanikas L.-A Hwang J. Pearson C.-S Ong V. Apostolopoulos H. Vaughan et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 Fusion Protein J Clin Invest 100 1997 2783-2792
15. H.J. Ditzel Human antibodies in cancer and autoimmune disease Immunol Res 21 2000 185-193
16. E. Stockert E. Jager Y.T. Chen M.J. Scanlan I. Gout J. Karbach et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens J Exp Med 187 1998 1349-1354
17. U. Behrends I. Schneider S. Rossler H. Frauenknecht A. Golbeck B. Lechner et al. Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries Int J Cancer 106 2003 244-251
18. D. Jager E. Stockert J. Karbach K. Herrlinger A. Atmaca M. Arand et al. Urine antibody against human cancer antigen NY-ESO-1 Cancer Immun 2 2002 10-18
19. A. Thor F. Gorstein N. Ohuchi C.A. Szpak W.W. Johnston J. Schlom Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3 J Natl Cancer Inst 76 1986 995-1006
20. H. Yagita T. Masuko Y. Hashimoto Inhibition of tumor cell growth in vitro by murine monoclonal antibodies that recognize a proliferation-associated cell surface antigen system in rats and humans Cancer Res 46 1986 1478-1484
21. D. Herlyn H.F. Sears C.S. Ernst D. Iliopoulos Z. Steplewski H. Koprowski Initial clinical evaluation of two murine IgG2a monoclonal antibodies for immunotherapy of gastrointestinal carcinoma Am J Clin Oncol 14 1991 371-378
22. H. Koprowski M. Herlyn Z. Steplewski H.F. Sears Specific antigen in serum of patients with colon carcinoma Science 212 1981 53-55
23. R.A. Reisfeld D.A. Cheresh Human tumor antigens Adv Immunol 40 1987 323-377
24. N.S. Rote R.K. Gupta D.L. Morton Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasms J Surg Res 29 1980 18-22
25. N.S. Rote R.K. Gupta D.L. Morton Determination of incidence and partial characterization of tumor-associated antigens found in the urine of patients bearing solid tumors Int J Cancer 26 1980 203-210
26. D.M. Euhus R.K. Gupta D.L. Morton Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients Int J Cancer 45 1990 1065-1070
27. C. Hetzitheofilou D.H. Kern R.K. Gupta M.A. Campbell D.L. Morton A radioimmunometric assay for the detection and characterization of lung cancer-associated antibodies in sera of lung cancer patients J Surg Res 42 1987 85-91
28. M.C. Kelley R.C. Jones R.K. Gupta R. Yee S. Stern L. Wanek et al. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma Cancer 83 1998 1355-1361
29. D.M. Euhus R.K. Gupta D.L. Morton Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine Cancer Immunol Immunother 29 1989 247-254
30. R.C. Jones M.C. Kelley R.K. Gupta J.A. Nizze R. Yee Z. Leopoldo et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model Ann Surg Oncol 3 1996 437-445
31. R.K. Gupta J.F. Huth E.L. Korn D.L. Morton Prognostic significance of urinary antigen analysis by enzyme-linked immunosorbent assay in melanoma patients Diagn Immunol 1 1983 303-309
32. D.M. Euhus R.K. Gupta D.L. Morton Detection of a tumor-associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1-40F4) in enzyme immunoassay J Clin Lab Anal 3 1989 184-190
33. Gupta RK, Morton DL. Glycoprotein tumor-associated antigen specific immune complex in sera of breast cancer patients. In: XVI International Cancer Congress, Monduzzi Editore, Bologna, Italy, 1994;1333-1337.
34. D.M. Euhus R.K. Gupta D.L. Morton Association between allo-immunoreactive and xeno-immunoreactive subunits of a glycoprotein tumor-associated antigen Cancer Immunol Immunother 32 1990 214-220
35. R.K. Gupta D.L. Morton Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen specific immune complexes in cancer patients J Clin Lab Anal 6 1992 329-336
36. R.L. Barbieri J.M. Niloff R.C. Bast Jr. E. Scaetzl R.W. Kistner R.C. Knapp Elevated serum concentrations of CA-125 in patients with advanced endometreiosis Fertil Steril 45 1986 630-634
37. S. Metcalfe T.K. Wheeler S. Picken S. Negus A. Jo Milner P53 autoantibodies in 1006 patients followed up for breast cancer Breast Cancer Res 2 2000 438-443
38. P. Lenner F. Wiklund S.O. Emdin C. Arnerlov C. Eklund G. Hallmans et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: A population-based epidemiological study Br J Cancer 79 1999 927-932
39. M.H. Chung R.K. Gupta R. Essner W. Ye R. Yee D.L. Morton Serum TA90 immune complex assay can predict outcome after resection of thick (≥ 4 mm) primary melanoma and sentinel lymphadenectomy Ann Surg Oncol 9 2002 120-126
40. D.A. Litvak R.K. Gupta R. Yee L.A. Wanek W. Ye D.L. Morton Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors J Am Coll Surg 198 2004 27-35
41. M.C. Kelley R.K. Gupta E.C. Hsueh R. Yee S. Stern D.L. Morton Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma J Clin Oncol 19 2001 1176-1182
42. L. Tafra P.S. Dale L.A. Wanek K.P. Ramming D.L. Morton Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax J Thorac Cardiovasc Surg 110 1995 119-129
43. D.L. Morton D.W. Ollila E.C. Hsueh R. Essner R.K. Gupta Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma CA Cancer J Clin 49 1999 101-116
44. E.C. Hsueh R.K. Gupta K. Qi R. Yee Z.C. Leopoldo D.L. Morton TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma Cancer J Sci Am 3 1997 364-370
45. E.C. Hsueh R.K. Gupta E.C. Glass R. Yee K. Qi D.L. Morton Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma J Am Coll Surg 187 1998 191-197
46. N. Habal R.K. Gupta A.J. Bilchik T. Johnson D.L. Morton TA90-IC, a new marker for advanced colon cancer Ann Surg Oncol 7 2000 352-356
47. S. Kakari E. Stringou M. Toumbis A.S. Ferderigos E. Poulaki K. Chondros et al. Five tumor markers in lung cancer: Significance of total and "lipid"-bound sialic acid Anticancer Res 11 1991 2107-2110
48. J. Trape J. Buxo J. Perez de Olaguer C. Vidal Tumor markers as prognostic factors in treated non-small cell lung cancer Anticancer Res 23 2003 4277-4281
49. R. Molina X. Filella J.M. Auge R. Fuentes I. Bover J. Rifa et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors Tumour Biol 24 2003 209-218
50. G. Buccheri D. Ferrigno Lung cancer in North-West Italy: Demographic and clinical trends in a hospital-based population of 1277 patients Eur J Cancer Prev 12 2003 455-461
51. R.K. Gupta D.L. Morton Prognostic value of a 90kD subunit containing glycoprotein tumor-associated antigen immune complexes in lung cancer patients Dis Markers 12 1994 51-61
52. R. Molina Tumor markers in breast cancer. In: E.P. Diamandis H.A. Fritsche H. Lilja D.W. Chan M.K. Schwartz (Eds.) Tumor markers: physiology, pathobiology, technology, and clinical applications 2002 AACC Press Washington DC 165-179
53. J.F. Robertson D. Pearson M.R. Price C. Selby R.W. Blamey A. Howell Objective measurement of therapeutic response in breast cancer using tumour markers Br J Cancer 64 1991 757-763
54. C. Tondini D.F. Hayes R. Gelman I.C. Henderson D.W. Kufe Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer Cancer Res 48 1988 4107-4112
55. D.M. O'Hanlon M.J. Kerin P.J. Kent R. Skehill D. Maher H. Grimes et al. A prospective evaluation of CA15-3 in stage I carcinoma of the breast J Am Coll Surg 180 1995 210-212
56. R. Molina X. Filella G. Zanon J. Pahisa J. Alicarte M. Munoz et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15-3) in patients with locoregional breast cancer Anticancer Res 23 2003 1043-1050
57. R.K. Gupta D.L. Morton Detection and comparison of a 90kD glycoprotein tumor-associated antigen immune complexes with CEA and CA15-3 in breast cancer Int J Oncol 7 1995 741-747
58. M.P. Look W.L. van Putten M.J. Duffy N. Harbeck I.J. Christensen C. Thomssen et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients J Natl Cancer Inst 94 2002 116-128
59. J.A. Foekens J. Kos H.A. Peters M. Krasovec M.P. Look N. Cimerman et al. Prognostic significance of cathepsins B and L in primary human breast cancer J Clin Oncol 16 1998 1013-1021
60. J.S. Ng C.M. Sturgeon J. Seth G.M. Paterson J.E. Roulston R.C. Leonard Serological markers for metastatic breast cancer Dis Markers 11 1993 217-223